Jupiter Neurosciences, Inc. JUNS
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -97.12%
- 1 year
- -97.84%
- Market cap
- 2.90M
- EPS (ttm)
- -18.94
- Shares out
- 32.88M
- YTD return
- -97.12%
- 1-year return
- -97.84%
- Volume
- 25.34K
- Avg volume
- 896.62K
- Open
- 2.10
- Previous close
- 2.13
- Day's range
- 2.01 – 2.27
- 52-week range
- 2.05 – 103.50
- Analysts
- Strong Buy
- Price target
- 30.00 (+1263.6%)
1Y -97.55 (-97.79%)
Key statistics
- Enterprise value
- 295.46M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 14.85K
- Total debt
- 2.34M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 9.68
- 200-day average
- 9.68
Analyst view
Consensus: strong buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.02.
Financials — quick view
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson's disease. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jupiterneurosciences.com
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease - 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session 
Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results - 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on JUNS — it syncs with the Stock Master app.